291 related articles for article (PubMed ID: 37051296)
1. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors.
Zhang Y; Cheng S; Zou H; Han Z; Xie T; Zhang B; Dai D; Yin X; Liang Y; Kou Y; Tan Y; Shen L; Peng Z
Front Cell Infect Microbiol; 2023; 13():1099063. PubMed ID: 37051296
[TBL] [Abstract][Full Text] [Related]
2. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome for predicting immune checkpoint blockade-associated adverse events.
Hu M; Lin X; Sun T; Shao X; Huang X; Du W; Guo M; Zhu X; Zhou Y; Tong T; Guo F; Han T; Wu X; Shi Y; Xiao X; Zhang Y; Hong J; Chen H
Genome Med; 2024 Jan; 16(1):16. PubMed ID: 38243343
[TBL] [Abstract][Full Text] [Related]
4. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
Chau J; Yadav M; Liu B; Furqan M; Dai Q; Shahi S; Gupta A; Mercer KN; Eastman E; Hejleh TA; Chan C; Weiner GJ; Cherwin C; Lee STM; Zhong C; Mangalam A; Zhang J
BMC Cancer; 2021 Jul; 21(1):808. PubMed ID: 34256732
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.
Liu W; Ma F; Sun B; Liu Y; Tang H; Luo J; Chen H; Luo Z
Front Immunol; 2021; 12():756872. PubMed ID: 34975845
[TBL] [Abstract][Full Text] [Related]
6. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.
Usyk M; Pandey A; Hayes RB; Moran U; Pavlick A; Osman I; Weber JS; Ahn J
Genome Med; 2021 Oct; 13(1):160. PubMed ID: 34641962
[TBL] [Abstract][Full Text] [Related]
7. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
8. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
[TBL] [Abstract][Full Text] [Related]
10.
Hamada K; Isobe J; Hattori K; Hosonuma M; Baba Y; Murayama M; Narikawa Y; Toyoda H; Funayama E; Tajima K; Shida M; Hirasawa Y; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Sambe T; Tsuji M; Wada S; Kiuchi Y; Kobayashi S; Kuramasu A; Horiike A; Kim YG; Tsunoda T; Yoshimura K
Front Immunol; 2023; 14():1164724. PubMed ID: 37207204
[TBL] [Abstract][Full Text] [Related]
11. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
12. Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations.
Wardill HR; Chan RJ; Chan A; Keefe D; Costello SP; Hart NH
Support Care Cancer; 2022 Aug; 30(8):6369-6373. PubMed ID: 35266052
[TBL] [Abstract][Full Text] [Related]
13. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
14. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.
Kubo T; Hirohashi Y; Tsukahara T; Kanaseki T; Murata K; Morita R; Torigoe T
Immunol Med; 2022 Jun; 45(2):108-118. PubMed ID: 34542015
[TBL] [Abstract][Full Text] [Related]
15. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events.
Liu X; Tang H; Zhou Q; Zeng Y; Lu B; Chen D; Li Y; Qian J; Chen M; Zhao J; Xu Y; Wang M; Tan B
Front Immunol; 2023; 14():1109281. PubMed ID: 36891304
[TBL] [Abstract][Full Text] [Related]
17. Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy.
Chau J; Zhang J
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360663
[TBL] [Abstract][Full Text] [Related]
18. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.
Nasca V; Barretta F; Corti F; Lonardi S; Niger M; Elez ME; Fakih M; Jayachandran P; Shah AT; Salati M; Fenocchio E; Salvatore L; Cremolini C; Ros J; Ambrosini M; Mazzoli G; Intini R; Overman MJ; Miceli R; Pietrantonio F
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593068
[TBL] [Abstract][Full Text] [Related]
19. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
20. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V
J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
